Related Experiment Videos
[Allogeneic peripheral blood stem cell transplantation for multiple myeloma]
1Department of Internal Medicine, Kokura Memorial Hospital.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|November 19, 1997
Summary
This study details a successful allogeneic stem cell transplant for refractory multiple myeloma. The patient achieved full donor chimerism with no graft-versus-host disease or graft failure.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
- Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for refractory multiple myeloma.
- Graft-versus-host disease (GVHD) and graft failure are significant complications following allogeneic HSCT.
Observation:
- A 46-year-old male patient with refractory multiple myeloma underwent allogeneic peripheral blood stem cell transplantation from an HLA-matched sibling.
- The conditioning regimen included total body irradiation (TBI), VP16, and cyclophosphamide.
- Graft-versus-host disease (GVHD) prophylaxis involved cyclosporine A and methotrexate.
Findings:
- Neutrophil engraftment occurred on day 12, and platelet engraftment on day 15.
- The patient experienced no GVHD or graft failure.
- Complete donor chimerism was achieved.
Implications:
- This case demonstrates the efficacy of allogeneic HSCT with a specific conditioning and GVHD prophylaxis regimen in managing refractory multiple myeloma.
- Successful engraftment and absence of GVHD suggest a favorable outcome for this patient.
- Further research can explore optimizing conditioning and GVHD prophylaxis strategies for multiple myeloma patients undergoing HSCT.